ALGS

About ALGS

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics to address unmet medical needs in viral and liver diseases. It uses its oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens. It is initially focused on developing functional cure for Chronic Hepatitis B (CHB); cirrhosis, end-stage liver disease (ESLD), and cirrhosis, end-stage liver disease (ESLD). It has developed a portfolio of differentiated drug candidates for CHB, including a small molecule Capsid Assembly Modulator (CAM) and oligonucleotides (Antisense Oligonucleotides (ASO) and Small Interfering Ribonucleic Acids (siRNA)), each of which is designed against clinically validated targets in the Hepatitis B Virus (HBV) life cycle. Its pipeline includes ALG 000184 (CAM) for CHB; ALG 020572 (ASO) for HBV; ALG 055009 for the treatment of nonalcoholic steatohepatitis (NASH), and ALG-125755.